{'52WeekChange': 0.74886537,
 'SandP52WeekChange': None,
 'address1': '350 Fifth Avenue',
 'address2': '72nd Floor Suite 7240',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 11.3,
 'askSize': 1400,
 'averageDailyVolume10Day': 73175,
 'averageVolume': 79406,
 'averageVolume10days': 73175,
 'beta': None,
 'beta3Year': None,
 'bid': 9.58,
 'bidSize': 800,
 'bookValue': 4.25,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 11.5,
 'dayLow': 10.89,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.668,
 'enterpriseToRevenue': 13.953,
 'enterpriseValue': 187018704,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '431 890 6360',
 'fiftyDayAverage': 11.168,
 'fiftyTwoWeekHigh': 14.366,
 'fiftyTwoWeekLow': 5.8,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 9594460,
 'forwardEps': -1.93,
 'forwardPE': -5.6735754,
 'fromCurrency': None,
 'fullTimeEmployees': 85,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.14781,
 'heldPercentInstitutions': 0.63331,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/hookipapharma.com',
 'longBusinessSummary': 'HOOKIPA Pharma Inc., a clinical stage '
                        'biopharmaceutical company, develops '
                        'immune-therapeutics targeting infectious diseases and '
                        'cancers based on its proprietary arenavirus platform. '
                        "The company's lead infectious disease product "
                        'candidate is HB-101, which is in a randomized '
                        'double-blinded Phase II clinical trial in patients '
                        'awaiting kidney transplantation from '
                        'cytomegalovirus-positive donors. Its lead oncology '
                        'product candidates are HB-201 and HB-202 that are in '
                        'preclinical studies for the treatment of human '
                        'papillomavirus-positive cancers. The company has a '
                        'collaboration with Gilead Sciences, Inc. to develop '
                        'infectious disease product candidates intended to '
                        'support functional cures for chronic Hepatitis B '
                        'virus and human immunodeficiency virus infections. '
                        'HOOKIPA Pharma Inc. was founded in 2011 and is '
                        'headquartered in New York, New York.',
 'longName': 'HOOKIPA Pharma Inc.',
 'market': 'us_market',
 'marketCap': 280809472,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_571641905',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -44634000,
 'nextFiscalYearEnd': 1640908800,
 'open': 11.5,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -1.3,
 'phone': '431 890 6360',
 'previousClose': 11.56,
 'priceHint': 2,
 'priceToBook': 2.5764706,
 'priceToSalesTrailing12Months': 20.95124,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 11.5,
 'regularMarketDayLow': 10.89,
 'regularMarketOpen': 11.5,
 'regularMarketPreviousClose': 11.56,
 'regularMarketPrice': 11.5,
 'regularMarketVolume': 53273,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 21825000,
 'sharesPercentSharesOut': 0.0319,
 'sharesShort': 819197,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 723729,
 'shortName': 'HOOKIPA Pharma Inc.',
 'shortPercentOfFloat': 0.0535,
 'shortRatio': 11.18,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'HOOK',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.859,
 'twoHundredDayAverage': 10.365647,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '4fc7c674-d2aa-3bcd-a128-4deb756f8490',
 'volume': 53273,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.hookipapharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10118'}